Cassava Sciences announced that long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered. Friedmann was a member of the Board of Directors since 1998 and Chief Medical Officer of the Company since 2001. James Kupiec, MD, who has been serving as Chief Clinical Development Officer of Cassava Sciences, will now serve as CMO for the Company, effective immediately. In addition, pursuant to a resolution duly adopted December 19, 2022, by majority vote of the remaining Board of Directors of Cassava Sciences, the number of directors which constitutes the entire Board of Directors is now fixed at six directors, the majority of whom still consists of independent outside directors.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SAVA:
- Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
- Cassava Sciences put volume heavy and directionally bearish
- Cassava Sciences call volume above normal and directionally bullish
- Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
- Cassava Sciences completes dosing in open-label study of simufilam
